Topic
Type 2 diabetes
4 reports, newest first.
twiist automated insulin delivery in type 2 diabetes: 13-week single-arm trial
In 307 adults with insulin-treated type 2 diabetes, 13 weeks of twiist automated insulin delivery was followed by lower HbA1c and more time in range, without a control group.
Semaglutide in diabetic kidney disease: primary MRI outcomes not met in 52-week trial
In a 52-week randomised trial in type 2 diabetes and chronic kidney disease, semaglutide did not significantly alter the coprimary kidney MRI outcomes versus placebo. Some secondary imaging and tissue findings favoured it.
ADA and EASD 2026 consensus: earlier SGLT2 inhibitor and/or GLP-1-based therapy in type 2 diabetes
The updated ADA and EASD consensus widens the focus from glucose control to holistic management and advocates earlier use, possibly from diagnosis, of SGLT2 inhibitors or GLP-1-based therapies.
Oral safiglipron versus dapagliflozin in type 2 diabetes: phase 3 trial in China
In a 32-week phase 3 trial in China, the oral GLP-1 receptor agonist safiglipron was non-inferior to dapagliflozin for HbA1c lowering, with more gastrointestinal side effects.
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.